Genomic signatures of breast cancer metastasis

V. Urquidi, Steven Goodison

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Despite significant advances in the treatment of primary cancer, the ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate such recurrences, remain major clinical challenges in oncology. While many potential molecular biomarkers have been identified and tested previously, none have greatly improved the accuracy of specimen evaluation over routine histopathological criteria and they predict individual outcomes poorly. However, the recent introduction of high-throughput microarray technology has opened new avenues in genomic investigation of cancer, and through application in tissue-based studies and appropriate animal models, has facilitated the identification of gene expression signatures that are associated with the lethal progression of breast cancer. The use of these approaches has the potential to greatly impact our knowledge of tumor biology, to provide efficient biomarkers, and enable development towards customized prognostication and therapies for the individual.

Original languageEnglish (US)
Pages (from-to)116-129
Number of pages14
JournalCytogenetic and Genome Research
Volume118
Issue number2-4
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Neoplasms
Biomarkers
Transcriptome
Animal Models
Technology
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • Cell Biology

Cite this

Genomic signatures of breast cancer metastasis. / Urquidi, V.; Goodison, Steven.

In: Cytogenetic and Genome Research, Vol. 118, No. 2-4, 01.11.2007, p. 116-129.

Research output: Contribution to journalReview article

@article{2be37dca57b949d2816583846b2cb50c,
title = "Genomic signatures of breast cancer metastasis",
abstract = "Despite significant advances in the treatment of primary cancer, the ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate such recurrences, remain major clinical challenges in oncology. While many potential molecular biomarkers have been identified and tested previously, none have greatly improved the accuracy of specimen evaluation over routine histopathological criteria and they predict individual outcomes poorly. However, the recent introduction of high-throughput microarray technology has opened new avenues in genomic investigation of cancer, and through application in tissue-based studies and appropriate animal models, has facilitated the identification of gene expression signatures that are associated with the lethal progression of breast cancer. The use of these approaches has the potential to greatly impact our knowledge of tumor biology, to provide efficient biomarkers, and enable development towards customized prognostication and therapies for the individual.",
author = "V. Urquidi and Steven Goodison",
year = "2007",
month = "11",
day = "1",
doi = "10.1159/000108292",
language = "English (US)",
volume = "118",
pages = "116--129",
journal = "Cytogenetic and Genome Research",
issn = "1424-8581",
publisher = "S. Karger AG",
number = "2-4",

}

TY - JOUR

T1 - Genomic signatures of breast cancer metastasis

AU - Urquidi, V.

AU - Goodison, Steven

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Despite significant advances in the treatment of primary cancer, the ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate such recurrences, remain major clinical challenges in oncology. While many potential molecular biomarkers have been identified and tested previously, none have greatly improved the accuracy of specimen evaluation over routine histopathological criteria and they predict individual outcomes poorly. However, the recent introduction of high-throughput microarray technology has opened new avenues in genomic investigation of cancer, and through application in tissue-based studies and appropriate animal models, has facilitated the identification of gene expression signatures that are associated with the lethal progression of breast cancer. The use of these approaches has the potential to greatly impact our knowledge of tumor biology, to provide efficient biomarkers, and enable development towards customized prognostication and therapies for the individual.

AB - Despite significant advances in the treatment of primary cancer, the ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate such recurrences, remain major clinical challenges in oncology. While many potential molecular biomarkers have been identified and tested previously, none have greatly improved the accuracy of specimen evaluation over routine histopathological criteria and they predict individual outcomes poorly. However, the recent introduction of high-throughput microarray technology has opened new avenues in genomic investigation of cancer, and through application in tissue-based studies and appropriate animal models, has facilitated the identification of gene expression signatures that are associated with the lethal progression of breast cancer. The use of these approaches has the potential to greatly impact our knowledge of tumor biology, to provide efficient biomarkers, and enable development towards customized prognostication and therapies for the individual.

UR - http://www.scopus.com/inward/record.url?scp=36248931070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248931070&partnerID=8YFLogxK

U2 - 10.1159/000108292

DO - 10.1159/000108292

M3 - Review article

VL - 118

SP - 116

EP - 129

JO - Cytogenetic and Genome Research

JF - Cytogenetic and Genome Research

SN - 1424-8581

IS - 2-4

ER -